Stock Analysis on Net

CVS Health Corp. (NYSE:CVS)

$24.99

Analysis of Goodwill and Intangible Assets

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Goodwill and Intangible Asset Disclosure

CVS Health Corp., balance sheet: goodwill and intangible assets

US$ in millions

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Goodwill
Trademark
Indefinitely-lived intangible assets
Customer contracts/relationships and covenants not to compete
Technology
Provider networks
Value of Business Acquired
Other
Finitely-lived intangible assets, gross carrying amount
Accumulated amortization
Finitely-lived intangible assets, net carrying amount
Intangible assets
Goodwill and other intangibles

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).


The financial data reveals several key trends regarding the intangible assets of the company over a five-year period from December 31, 2020, to December 31, 2024.

Goodwill
The goodwill value shows a slight downward trend from 79,552 million USD in 2020 to 78,150 million USD in 2022, followed by a significant increase to 91,272 million USD in 2023, where it remains stable into 2024. This indicates a potential acquisition or revaluation event in 2023 that boosted goodwill substantially.
Trademark and Indefinitely-lived Intangible Assets
Both trademarks and indefinitely-lived intangible assets maintain a constant value at 10,498 million USD throughout the period. This stability suggests no impairment or additional intangible asset recognition in these categories.
Customer Contracts/Relationships and Covenants Not to Compete
These assets fluctuate, initially increasing slightly from 24,952 million USD in 2020 to 25,084 million USD in 2021, then decreasing sharply to 21,206 million USD in 2022. The value rebounds significantly to 26,784 million USD in 2023 and slightly increases to 26,904 million USD in 2024, highlighting volatile valuation possibly influenced by contract renewals or renegotiations.
Technology
The technology intangible asset remains stable at 1,060 million USD from 2020 to 2022, followed by a moderate increase to approximately 1,250 million USD in 2023 and 2024. This gradual rise may reflect increased investment in or capitalization of technological capabilities.
Provider Networks and Value of Business Acquired
Both provider networks and the value of business acquired remain steady across all years, at 4,203 million USD and 590 million USD respectively, suggesting no changes or impairments in these categories.
Other Intangibles
The category labeled "Other" shows stability around the low 300s million USD from 2020 to 2022, followed by a sharp increase to over 830 million USD in 2023 and a slight decrease in 2024. This pattern could reflect recognition of new or reclassified intangible items in 2023.
Finitely-lived Intangible Assets
The gross carrying amount of finitely-lived intangible assets declines from 31,125 million USD in 2020 to 27,361 million USD in 2022 before rebounding to 33,773 million USD by 2024. Meanwhile, accumulated amortization steadily increases each year (in absolute terms), rising from 10,481 million USD in 2020 to 16,948 million USD in 2024. The net carrying amount mirrors these movements, decreasing significantly through 2022 and then partially recovering, which aligns with asset additions or revaluations balanced against ongoing amortization charges.
Total Intangible Assets and Goodwill & Other Intangibles
Total intangible assets decrease from 31,142 million USD in 2020 to 24,782 million USD in 2022, followed by an increase back to approximately 27,323 million USD in 2024. Similarly, the aggregate of goodwill and other intangible assets declines through 2022 from 110,694 million USD to 102,932 million USD, then significantly increases to 120,506 million USD in 2023 before settling at 118,595 million USD in 2024. This overall pattern suggests a period of asset write-down or disposals up to 2022, combined with a subsequent phase of acquisitions or asset recognition in 2023.

In summary, the analysis shows a general trend of reduction in intangible asset values until 2022, particularly in goodwill and finitely-lived assets, followed by a notable recovery and growth phase in 2023. This shift may reflect changes in corporate strategy, acquisitions, or adjustments to asset valuation methods. Amortization continues steadily, increasing accumulated amortization consistently over the years, impacting net intangible assets. Certain assets exhibit stability, while others fluctuate, indicating selective growth and reassessment within the intangible asset portfolio.


Adjustments to Financial Statements: Removal of Goodwill

CVS Health Corp., adjustments to financial statements

US$ in millions

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Adjustment to Total Assets
Total assets (as reported)
Less: Goodwill
Total assets (adjusted)
Adjustment to Total CVS Health Shareholders’ Equity
Total CVS Health shareholders’ equity (as reported)
Less: Goodwill
Total CVS Health shareholders’ equity (adjusted)
Adjustment to Net Income Attributable To CVS Health
Net income attributable to CVS Health (as reported)
Add: Goodwill impairment
Net income attributable to CVS Health (adjusted)

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).


The financial data reveals several notable trends regarding asset levels, shareholders' equity, and net income over the five-year period.

Total Assets
The reported total assets demonstrate a generally stable but slightly fluctuating pattern, ranging from approximately $230.7 billion in 2020, dipping marginally in 2022, then rising to about $253.2 billion by 2024. This indicates a modest overall growth in the asset base over the period.
When adjusted for goodwill, total assets show a similar pattern but at substantially lower absolute levels, reflecting the exclusion of goodwill values. Adjusted assets remain relatively steady, with a slight decline in 2022 followed by a gradual increase through 2024, implying consistent asset quality aside from goodwill effects.
Shareholders' Equity
Reported shareholders' equity experienced a general upward trend from approximately $69.4 billion in 2020 to a peak around $76.5 billion in 2023, followed by a small decline to $75.6 billion in 2024. This suggests moderate net value accretion for equity holders within the period, with some backward movement in the final year.
Adjusted shareholders' equity, after deducting goodwill, presents a markedly different trajectory. The figures are negative throughout, with a worsening position from -$10.2 billion in 2020 to nearly -$15.7 billion in 2024. The deepening negative equity on an adjusted basis points to substantial goodwill impairments or other intangible asset adjustments affecting the equity base.
Net Income
Reported net income shows volatility, starting at approximately $7.2 billion in 2020 and rising to a peak of $8.3 billion in 2023. The figure drops sharply to $4.6 billion in 2024, indicating a significant decrease in profitability in the most recent year.
Adjusted net income closely aligns with reported net income values, except in 2021 when it appears slightly higher. This suggests that goodwill adjustments have minimal impact on net income figures over most years except for that period. The decline in net income in 2024 is consistent across both reported and adjusted measures.

In summary, reported figures indicate stable asset growth and equity expansion with some recent earnings volatility, while adjustments for goodwill reveal underlying challenges in equity valuation, with negative adjusted equity expanding. The sharp drop in net income in the last year warrants further investigation to understand contributing factors.


CVS Health Corp., Financial Data: Reported vs. Adjusted


Adjusted Financial Ratios: Removal of Goodwill (Summary)

CVS Health Corp., adjusted financial ratios

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Net Profit Margin
Reported net profit margin
Adjusted net profit margin
Total Asset Turnover
Reported total asset turnover
Adjusted total asset turnover
Financial Leverage
Reported financial leverage
Adjusted financial leverage
Return on Equity (ROE)
Reported ROE
Adjusted ROE
Return on Assets (ROA)
Reported ROA
Adjusted ROA

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).


The financial data indicates several notable trends and variations over the period from 2020 to 2024.

Net Profit Margin
The reported net profit margin shows a fluctuating pattern, starting at 2.68% in 2020, experiencing a slight increase to 2.72% in 2021, then sharply declining to 1.29% in 2022. It recovers to 2.34% in 2023 before decreasing again to 1.24% in 2024. The adjusted net profit margin follows a similar trajectory, with a slightly higher peak at 2.87% in 2021, then mirroring the decline and partial recovery observed in the reported figures.
Total Asset Turnover
There is a consistent upward trend in both reported and adjusted total asset turnover ratios over the five-year period. Reported turnover increases steadily from 1.16 in 2020 to 1.46 in 2024. Adjusted total asset turnover values, where available, are significantly higher, rising from 1.77 in 2020 to 2.29 in 2024, indicating improved efficiency in asset utilization when adjustments are made.
Financial Leverage
The reported financial leverage ratio declines from 3.32 in 2020 to 3.10 in 2021, then shows a gradual increase through 2024, reaching 3.35. No adjusted financial leverage data is provided for comparison, limiting insights into leverage adjustments.
Return on Equity (ROE)
The reported ROE exhibits considerable variability, starting at 10.35% in 2020, peaking slightly at 10.54% in 2021, then dropping substantially to 5.84% in 2022. It rebounds to 10.91% in 2023 but falls again to 6.11% in 2024. Absence of adjusted ROE data prevents further comparative analysis.
Return on Assets (ROA)
Reported ROA follows a declining and recovering pattern similar to ROE and net profit margin, decreasing from 3.11% in 2020 to 1.82% in 2022, recovering to 3.34% in 2023, and then falling back to 1.82% in 2024. Adjusted ROA values are consistently higher across available years, with a more pronounced recovery and less severe declines, moving from 4.75% in 2020 to 5.42% in 2021, dropping to 2.76% in 2022, rebounding to 5.27% in 2023, and slightly declining to 2.85% in 2024.

Overall, the data suggests volatility in profitability metrics, particularly net profit margin and returns, over the assessed period. Asset turnover ratios indicate improving operational efficiency, especially when adjusted data is considered. The financial leverage ratio remains relatively stable with a slight upward trend in the later years. The adjusted figures for return on assets and asset turnover consistently outperform reported figures, implying that goodwill adjustments have a significant impact on efficiency and profitability measurement.


CVS Health Corp., Financial Ratios: Reported vs. Adjusted


Adjusted Net Profit Margin

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
As Reported
Selected Financial Data (US$ in millions)
Net income attributable to CVS Health
Revenues from customers
Profitability Ratio
Net profit margin1
Adjusted for Goodwill
Selected Financial Data (US$ in millions)
Adjusted net income attributable to CVS Health
Revenues from customers
Profitability Ratio
Adjusted net profit margin2

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

2024 Calculations

1 Net profit margin = 100 × Net income attributable to CVS Health ÷ Revenues from customers
= 100 × ÷ =

2 Adjusted net profit margin = 100 × Adjusted net income attributable to CVS Health ÷ Revenues from customers
= 100 × ÷ =


The analysis of the annual financial data reveals notable fluctuations in both reported and adjusted net income attributable to the company over the five-year period. Reported net income initially increased from 7,179 million US dollars in 2020 to 7,910 million US dollars in 2021, followed by a sharp decline to 4,149 million US dollars in 2022. This was succeeded by a recovery to 8,344 million US dollars in 2023 before experiencing another decrease to 4,614 million US dollars in 2024. The adjusted net income, available for three years in the series, closely mirrors the reported figures for corresponding years, indicating limited impact of goodwill adjustments during these periods.

Regarding profitability, the reported net profit margin displayed a declining trend overall, starting at 2.68% in 2020 and increasing marginally to 2.72% in 2021 before falling sharply to 1.29% in 2022. It partially rebounded to 2.34% in 2023, then declined again to 1.24% by 2024. The adjusted net profit margin follows a similar pattern, with a slightly higher margin in 2021 (2.87%) compared to the reported figure, suggesting some adjustment effects that improved the profitability metric in that year. The adjusted margins align exactly with reported margins in 2022, 2023, and 2024, consistent with the identical net income figures in those years.

Overall, the financial indicators demonstrate volatile profitability and net income performance across the period, with no consistent upward or downward trajectory. The variations between reported and adjusted results are minimal, except for a moderate beneficial adjustment in net profit margin in 2021. The observed fluctuations in net income and profit margins may be indicative of external market conditions or operational challenges affecting earnings stability during this timeframe.


Adjusted Total Asset Turnover

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
As Reported
Selected Financial Data (US$ in millions)
Revenues from customers
Total assets
Activity Ratio
Total asset turnover1
Adjusted for Goodwill
Selected Financial Data (US$ in millions)
Revenues from customers
Adjusted total assets
Activity Ratio
Adjusted total asset turnover2

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

2024 Calculations

1 Total asset turnover = Revenues from customers ÷ Total assets
= ÷ =

2 Adjusted total asset turnover = Revenues from customers ÷ Adjusted total assets
= ÷ =


The financial data reveals distinct trends in the company's asset base and efficiency measures over the five-year period from 2020 to 2024. Both reported and adjusted total assets exhibit moderate fluctuations, with an overall slight increase observed by the end of the timeframe.

Total Assets
Reported total assets started at 230,715 million US dollars in 2020 and showed minor variation reaching 253,215 million US dollars by 2024. This reflects an increase of approximately 9.7% over the five years.
Adjusted total assets, which exclude goodwill, consistently show lower values but follow a similar pattern with slight fluctuations. These assets rose from 151,163 million US dollars in 2020 to 161,943 million US dollars in 2024, amounting to an approximate 7.1% increase.
Total Asset Turnover Ratios
The reported total asset turnover ratio exhibits a positive upward trajectory, increasing from 1.16 in 2020 to 1.46 in 2024. This indicates improving efficiency in generating revenue relative to the asset base.
Adjusted total asset turnover, representing efficiency excluding goodwill, starts at a higher ratio of 1.77 and increases to 2.29 by 2024. The ratio has steadily risen each year, emphasizing enhanced utilization of core assets in revenue generation.

Overall, the data indicates that the company slightly expanded its asset base during the period but achieved significantly improved operational efficiency, particularly when considering the goodwill-adjusted asset base. This suggests effective management of assets leading to stronger revenue generation capabilities over time.


Adjusted Financial Leverage

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
As Reported
Selected Financial Data (US$ in millions)
Total assets
Total CVS Health shareholders’ equity
Solvency Ratio
Financial leverage1
Adjusted for Goodwill
Selected Financial Data (US$ in millions)
Adjusted total assets
Adjusted total CVS Health shareholders’ equity
Solvency Ratio
Adjusted financial leverage2

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

2024 Calculations

1 Financial leverage = Total assets ÷ Total CVS Health shareholders’ equity
= ÷ =

2 Adjusted financial leverage = Adjusted total assets ÷ Adjusted total CVS Health shareholders’ equity
= ÷ =


The reported total assets exhibited a generally moderate upward trend over the analyzed period. Starting at approximately $230.7 billion in 2020, the figure marginally increased to around $232.9 billion in 2021 before experiencing a slight decrease to about $228.3 billion in 2022. Subsequently, the total assets increased more significantly in 2023 and 2024, reaching approximately $249.7 billion and $253.2 billion respectively. This suggests measured growth in asset base towards the later years.

In contrast, the adjusted total assets, which exclude goodwill, show a more stable yet slightly declining trend. Beginning at approximately $151.2 billion in 2020, there was a mild increase to about $153.9 billion in 2021, followed by a gradual decline to roughly $150.1 billion in 2022. Thereafter, a moderate rebound is observed with adjusted assets rising to $158.5 billion in 2023 and $161.9 billion in 2024. This pattern indicates some fluctuation after adjustment, but overall a modest growth by the end of the period.

Reported total shareholders’ equity shows a fluctuating pattern with a generally upward trajectory. Equity increased from about $69.4 billion in 2020 to $75.1 billion in 2021. However, there was a decline in 2022, dropping to roughly $71.0 billion, followed by an increase to nearly $76.5 billion in 2023. A slight decrease occurred in 2024, reducing equity to approximately $75.6 billion. This reflects some volatility in equity levels but generally positive growth over the five-year period.

Adjusted shareholders’ equity, however, presents a markedly different and negative trend. Starting significantly negative at approximately -$10.2 billion in 2020, it worsened to around -$4.0 billion in 2021 but then deteriorated again in subsequent years reaching roughly -$7.1 billion in 2022 and further declining to about -$14.8 billion in 2023 and -$15.7 billion in 2024. This persistent negative adjusted equity suggests substantial goodwill or intangible asset impairments or adjustments impacting the net equity position negatively.

The reported financial leverage ratio, which measures the relationship between total assets and equity, shows a decline from 3.32 in 2020 to 3.10 in 2021, suggesting relatively less leverage in that year. It then increases again to 3.21 in 2022, followed by a further rise to 3.27 in 2023 and 3.35 in 2024, indicating an increasing reliance on liabilities to finance the assets towards the latter years. No data was available for adjusted financial leverage, which could have provided insight into leverage excluding goodwill effects.

Overall, the data demonstrate that the company's reported assets and equity are generally expanding, but adjustments removing goodwill reveal underlying weakness in equity. The negative and worsening adjusted shareholders’ equity underscores potential risks related to asset valuation or goodwill impairment. The increasing reported financial leverage in recent years suggests a trend toward greater use of debt relative to equity, which investors and stakeholders should monitor carefully.


Adjusted Return on Equity (ROE)

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
As Reported
Selected Financial Data (US$ in millions)
Net income attributable to CVS Health
Total CVS Health shareholders’ equity
Profitability Ratio
ROE1
Adjusted for Goodwill
Selected Financial Data (US$ in millions)
Adjusted net income attributable to CVS Health
Adjusted total CVS Health shareholders’ equity
Profitability Ratio
Adjusted ROE2

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

2024 Calculations

1 ROE = 100 × Net income attributable to CVS Health ÷ Total CVS Health shareholders’ equity
= 100 × ÷ =

2 Adjusted ROE = 100 × Adjusted net income attributable to CVS Health ÷ Adjusted total CVS Health shareholders’ equity
= 100 × ÷ =


The financial data over the five-year period exhibits notable fluctuations in net income, shareholders' equity, and return on equity (ROE) for the entity analyzed. Both reported and adjusted net incomes are presented, with the adjusted figures aligning closely to the reported net income levels except for a divergence noted in 2021.

Net Income Trends
The reported net income attributable to the company demonstrates variability, peaking in 2021 at US$7,910 million before experiencing a sharp decline to US$4,149 million in 2022. A recovery is evident in 2023, with net income reaching US$8,344 million, followed by another decrease in 2024 to US$4,614 million. The adjusted net income mirrors these trends closely, except in 2021 when it is marginally higher than the reported figure.
Shareholders’ Equity
Reported total shareholders’ equity shows a general upward trend from US$69,389 million in 2020 to a high of US$76,461 million in 2023, before slightly retreating to US$75,560 million in 2024. Conversely, the adjusted shareholders’ equity values are negative throughout the period and demonstrate increasing negative magnitude, worsening from -US$10,163 million in 2020 to -US$15,712 million in 2024, which indicates substantial deductions or adjustments impacting equity.
Return on Equity (ROE)
Reported ROE follows a pattern consistent with net income fluctuations, rising from 10.35% in 2020 to a peak of 10.91% in 2023, with notable dips to 5.84% in 2022 and 6.11% in 2024. Adjusted ROE data is not available for analysis, limiting insight into performance after accounting for adjustments.

Overall, the data points to volatility in profitability as measured by net income and ROE, with significant volatility particularly in the years 2022 and 2024. Shareholders’ equity shows a moderate increase in reported terms but deteriorates significantly when adjusted figures are considered, highlighting underlying challenges or accounting treatments that materially affect the equity base. The absence of adjusted ROE calculations precludes a full understanding of returns post-adjustment.


Adjusted Return on Assets (ROA)

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
As Reported
Selected Financial Data (US$ in millions)
Net income attributable to CVS Health
Total assets
Profitability Ratio
ROA1
Adjusted for Goodwill
Selected Financial Data (US$ in millions)
Adjusted net income attributable to CVS Health
Adjusted total assets
Profitability Ratio
Adjusted ROA2

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

2024 Calculations

1 ROA = 100 × Net income attributable to CVS Health ÷ Total assets
= 100 × ÷ =

2 Adjusted ROA = 100 × Adjusted net income attributable to CVS Health ÷ Adjusted total assets
= 100 × ÷ =


The financial data over the five-year period reveals notable fluctuations and trends in net income, total assets, and return on assets (ROA) for the company.

Net Income
Reported net income attributable to the company experienced variability, with an initial increase from 7,179 million US dollars in 2020 to 7,910 million in 2021, followed by a significant decline to 4,149 million in 2022. A recovery occurred in 2023 reaching 8,344 million, but this was again followed by a decrease to 4,614 million in 2024. The adjusted net income figures largely mirror this pattern, except for a slight upward adjustment in 2021, where the adjusted net income was 8,341 million compared to the reported 7,910 million.
Total Assets
Reported total assets showed moderate growth overall from 230,715 million US dollars in 2020 to 253,215 million in 2024, despite a dip in 2022 to 228,275 million. The adjusted total assets, which appear to exclude goodwill or other non-core assets, are significantly lower than reported totals but follow a similar trajectory, increasing from 151,163 million in 2020 to 161,943 million in 2024 with a slight decrease in 2022 to 150,125 million.
Return on Assets (ROA)
Both reported and adjusted ROA exhibit similar trends but differ in magnitude. Reported ROA fluctuated, starting at 3.11% in 2020, rising slightly to 3.39% in 2021, dropping to 1.82% in 2022, rebounding to 3.34% in 2023, and again declining to 1.82% in 2024. Adjusted ROA percentages are consistently higher than reported figures, beginning at 4.75% in 2020, peaking at 5.42% in 2021, then falling to 2.76% in 2022, increasing to 5.27% in 2023, and decreasing to 2.85% in 2024. This suggests that when goodwill and other adjustments are considered, the company's asset efficiency appears stronger but still follows the same cyclical pattern.

Overall, the data indicates cyclical performance with income and asset efficiency subject to fluctuations, including significant downturns in 2022 and 2024 followed by recoveries in 2023. The adjustments, primarily affecting asset values and consequently adjusted ROA, reflect a more favorable view of asset utilization excluding certain intangible assets. This cyclical pattern may warrant deeper investigation into underlying operational or market factors influencing financial results during these periods.